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African trypanosomiasis (Sleeping Sickness) 
By:  Pedro Garcia and Austin Burton 
Background 
Treatment 
Infection/Disease 
 
African sleeping sickness kills 50,000 people each year.  There are 60 million people at risk of 
catching the disease,  which is about two and a half times the population of Texas,  living in 36 
sub-Saharan African countries, an area a little bigger than the 48 contiguous states.  For each 
person diagnosed and treated for African sleeping sickness  twelve go undiagnosed and die. 
 
African Sleeping Sickness, also known as human African 
trypanosomiasis, is caused by the parasite trypanosomes.  
Trypanosomes are pathogenic protozoa.  Protozoa are 
unicellular organisms that do not have a cell wall and usually 
obtain food by ingesting other organisms.  African Sleeping 
Sickness usually stays in the blood stream, but in later stages the 
disease moves into the central nervous system, which can lead 
to fever, swollen lymph, headaches, mood changes, and 
sweating.  Trypanosomes have the ability to temporarily change 
their major surface antigens giving memory t cells problems.  
This is called Antigenic Variation and is believed to be the 
biggest cause for Trypanosomes’ survival in the body (Food and 
Agriculture Organization, 2014). 
There are two different stages of progression, before the sporozoan 
reaches the central nervous system and after the sporozoan 
reaches the central nervous system.  There are also two different 
types of African sleeping sickness, East and West, and different 
progression rates of each (CDC, 2014). 
 
East African Sleeping Sickness 
This is the more rapid of the two. Most patients will develop 
systems within 1-2 weeks of the infected bite happening.  After a 
few weeks it enters the central nervous system and this leads to 
mental deterioration and death usually follows within about a 
month  (CDC, 2014). 
 
This is the slower of the two methods.  Mild symptoms are to 
occur at first but after about a year or two the side effects at this 
point are personality changes, daytime sleepiness and night time 
disturbance and progressive confusion.  Partial paralysis or 
problems with walking will occur here as well.  Untreated it rarely 
last longer then 6-7 years and death usually happens within 3 
years.  Death can occur within 6 months without treatment from 
cardiac failure or from the infection itself which can cause the 
disease to get much worse much faster often over a few weeks 
(CDC, 2014). 
Importance:  The people most exposed to the tsetse fly have a 
better chance of getting the African sleeping sickness also known 
as African trypanosomiasis.  This sickness kills over 50,000 people 
per year in Africa.  This may not be important to us Americans but 
people are dying right now due to this sickness. African sleeping 
sickness is most prevalent in the area of East and West Africa.  
These areas have  a total square mileage of 252,791.  African 
trypanosomiasis is transmitted from person to person by a vector, 
the tsetse fly.  Sleeping sickness is rarely transmitted by blood 
transfusion or across the placenta during pregnancy because the 
disease causes infertility and spontaneous abortion in women of 
child-bearing age. The Rhodesians form is a zoonotic, with 
occasional infection of humans.  In the gambiense form, humans 
are regarded as the main reservoir that plays a key role in the 
transmission cycle of the disease (Food and Agriculture 
Organization, 2014). 
 
Historical: Modern history of African trypanosomiasis revolves 
around the identification of the causative agents and the mode of 
transmission of the infection, and the development of drugs for 
treatment and methods for control of the disease.  From the 
recent history of sleeping sickness we can learn that the disease 
can be controlled but probably not be eradicated.  Current history 
of human African trypanosomiasis has shown that the production 
of anti-sleeping sickness drugs is not always guaranteed, and 
therefore, new, better and cheaper drugs are urgently required 
(WHO, 2014).  
 
 
 
 
 
 
 
 
 
Micro Organism: The African sleeping sickness is known as a 
protist.  Sleeping sickness occurs only in 36 sub-Saharan Africa 
countries where there are tsetse flies that transmit the disease.  
The tsetse fly is large, brown and stealthy (NML). While taking 
blood from a mammalian host, an infected tsetse injects 
metacyclic trypomastigotes into skin tissue.  The parasites enter 
the lymphatic system and pass into the bloodstream (Seattle 
Biomed, 2015). 
Tsetse Fly 
Trypanosomes in the blood stream 
The type of treatment depends on the stage of the disease.  The drugs used 
in the first stage of the disease are of lower toxicity and easier to administer.  
The earlier the disease is identified, the better the prospect of a cure. 
Treatment success in the second stage depends on a drug that can cross the 
blood-brain barrier to reach the parasite.  Such drugs are toxic and 
complicated to administer.  Four drugs are registered for the treatment of 
sleeping sickness.  These drugs are donated to the World Health 
Organization (WHO) by manufacturers and distributed free of charge to 
countries endemic for the disease.  All persons diagnosed with African 
Trypanosomiasis should receive treatment.  The specific drug and treatment 
course will depend on the type of infection (Trypanosoma brucei  gambiense 
or Trypanosoma brucei  rhodesiense) and the disease stage (i.e., whether the 
central nervous system has been invaded by the parasite). Pentamidine, 
which is the recommended drug for first stage T. b. gambiense infection, is 
widely available in the U.S. The other drugs (suramin, melarsoprol, 
eflornithine, and nifurtimox) used to treat African trypanosomiasis are 
available in the U.S. only from the Centers for Disease Control  (CDC).  
Physicians can consult with CDC staff for advice on diagnosis and 
management and to obtain otherwise unavailable treatment drug.  With out 
treatment death is inevitable (National Institute of Health, n.d.).  
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